Hypertension (JNC-8)
|
|
- Augustus Ross Day
- 5 years ago
- Views:
Transcription
1 Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.!
2 The 8 th Joint National Committee Guidelines (2013) A. Joint National Committee-6 (1997) Classification of Blood Pressure for Adults Aged 18 Years & Older Category Systolic (mm Hg) Diastolic (mm Hg) rmal < 130 < 85 High rmal Hypertension Stage 1 (mild) Stage 2 (moderate) Stage 3 (severe) Stage 4 (very severe) > 210 > 120 B. Joint National Committee-7 (2003) Table 2. Changes in blood pressure classification JNC 6 Category SBP/DBP Optimal <120/80 rmal /80 84 Borderline /85 89 Hypertension >140/90 STAGE /90 99 JNC 7 Category rmal Prehypertension Hypertension STAGE 1 STAGE 2 STAGE / >180/110 STAGE 2 C. Joint National Committee-8 (2013) Patients > 60 years old, initiate pharm. tx at SBP > 150 OR DBP > 90 Patients < 60 years old, initiate pharm. tx SBP > 140 OR DBP > 90. Patients > 18 years with diabetes or CKD, initiate pharm. tx at SBP > 140 OR DBP > 90 General non-black population, including those with diabetes, initial pharm. tx should include a thiazide diuretic, CCB, ACE-I or ARB. (te: BB are omitted) General black population, initial treatment should include a thiazide diuretic or a CCB. (te: BB, ACE-I & ARB are omitted) All patients with CKD and HTN, initial treatment should include an ACE-I or an ARB to improve kidney outcomes. In all hypertensive patients, if goal BP is not reached within a month of initiating treatment, increase the dose of the initial drug OR add a second drug from one of these four classes. o If goal BP cannot be reached with two drugs, add and titrate a third drug from the list provided.
3 Figure Hypertension Guideline Management Algorithm Adult aged 18 years with hypertension Implement lifestyle interventions (continue throughout management). Set blood pressure goal and initiate blood pressure lowering-medication based on age, diabetes, and chronic kidney disease (CKD). General population (no diabetes or CKD) Diabetes or CKD present Age 60 years Age <60 years All ages Diabetes present CKD All ages CKD present with or without diabetes SBP <150 mm Hg SBP <140 mm Hg SBP <140 mm Hg SBP <140 mm Hg nblack Black All races Initiate thiazide-type diuretic or ACEI or ARB or CCB, alone or in combination. a Initiate thiazide-type diuretic or CCB, alone or in combination. Initiate ACEI or ARB, alone or in combination with other drug class. a Select a drug treatment titration strategy A. Maximize first medication before adding second or B. Add second medication before reaching maximum dose of first medication or C. Start with 2 medication classes separately or as fixed-dose combination. Reinforce medication and lifestyle adherence. For strategies A and B, add and titrate thiazide-type diuretic or ACEI or ARB or CCB (use medication class not previously selected and avoid combined use of ACEI and ARB). For strategy C, titrate doses of initial medications to maximum. Reinforce medication and lifestyle adherence. Add and titrate thiazide-type diuretic or ACEI or ARB or CCB (use medication class not previously selected and avoid combined use of ACEI and ARB). Reinforce medication and lifestyle adherence. Add additional medication class (eg, β-blocker, aldosterone antagonist, or others) and/or refer to physician with expertise in hypertension management. Continue current treatment and monitoring. b SBP indicates systolic blood pressure; DBP, diastolic blood pressure; ACEI, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and CCB, calcium channel blocker. a ACEIs and ARBs should not be used in combination. b If blood pressure fails to be maintained at goal, reenter the algorithm where appropriate based on the current individual therapeutic plan. 33 Downloaded From: on 09/13/2018
4 Adult aged 18 years with HTN Implement lifestyle modifications Set BP goal, initiate BP-lowering medication based on algorithm General Population (no diabetes or CKD) Black JNC 8 Hypertension Guideline Algorithm Diabetes or CKD present Age 60 years Age < 60 years All Ages Diabetes present CKD < 150/90 nblack Initiate thiazide, ACEI, ARB, or CCB, alone or in combo < 140/90 Initiate thiazide or CCB, alone or combo At blood pressure goal? < 140/90 All Ages and Races CKD present with or without diabetes < 140/90 Initiate ACEI or ARB, alone or combo w/another class Reinforce lifestyle and adherence Titrate medications to maximum doses or consider adding another medication (ACEI, ARB, CCB, Thiazide) At blood pressure goal? Reinforce lifestyle and adherence Add a medication class not already selected (i.e. beta blocker, aldosterone antagonist, others) and titrate above medications to max (see back of card) Initial Drugs of Choice for Hypertension ACE inhibitor (ACEI) Angiotensin receptor blocker (ARB) Thiazide diuretic Calcium channel blocker (CCB) Strategy A B C Description Start one drug, titrate to maximum dose, and then add a second drug. Start one drug, then add a second drug before achieving max dose of first Begin 2 drugs at same time, as separate pills or combination pill. Initial combination therapy is recommended if BP is greater than 20/10mm Hg above goal Lifestyle changes: Smoking Cessation Control blood glucose and lipids Diet Eat healthy (i.e., DASH diet) Moderate alcohol consumption Reduce sodium intake to no more than 2,400 mg/day Physical activity Moderate-to-vigorous activity 3-4 days a week averaging 40 min per session. At blood pressure goal? Reinforce lifestyle and adherence Titrate meds to maximum doses, add another med and/or refer to hypertension specialist Continue tx and monitoring Reference: James PA, Ortiz E, et al evidence-based guideline for the management of high blood pressure in adults: (JNC8). JAMA Feb 5;311(5): Card developed by Cole Glenn, Pharm.D. & James L Taylor, Pharm.D.
5 Indication Heart Failure Post MI/Clinical CAD CAD Diabetes CKD Recurrent stroke prevention Pregnancy Compelling Indications Treatment Choice ACEI/ARB + BB + diuretic + spironolactone ACEI/ARB AND BB ACEI, BB, diuretic, CCB ACEI/ARB, CCB, diuretic ACEI/ARB ACEI, diuretic labetolol (first line), nifedipine, methyldopa Hypertension Treatment Beta-1 Selective Beta-blockers possibly safer in patients with COPD, asthma, diabetes, and peripheral vascular disease: metoprolol bisoprolol betaxolol acebutolol Drug Class Agents of Choice Comments Diuretics HCTZ mg, chlorthalidone mg, indapamide mg triamterene 100mg K+ sparing spironolactone 25-50mg, amiloride 5-10mg, triamterene 100mg furosemide 20-80mg twice daily, torsemide 10-40mg ACEI/ARB ACEI: lisinopril, benazapril, fosinopril and quinapril 10-40mg, ramipril 5-10mg, trandolapril 2-8mg ARB: candesartan 8-32mg, valsartan mg, losartan mg, olmesartan 20-40mg, telmisartan 20-80mg Beta-Blockers Calcium channel blockers Vasodilators metoprolol succinate mg and tartrate mg twice daily, nebivolol 5-10mg, propranolol mg twice daily, carvedilol mg twice daily, bisoprolol 5-10mg, labetalol mg twice daily, Dihydropyridines: amlodipine 5-10mg, nifedipine ER 30-90mg, n-dihydropyridines: diltiazem ER mg, verapamil mg 3 times daily or ER mg hydralazine mg twice daily, minoxidil 5-10mg Monitor for hypokalemia Most SE are metabolic in nature Most effective when combined w/ ACEI Stronger clinical evidence w/chlorthalidone Spironolactone - gynecomastia and hyperkalemia Loop diuretics may be needed when GFR <40mL/min SE: Cough (ACEI only), angioedema (more with ACEI), hyperkalemia Losartan lowers uric acid levels; candesartan may prevent migraine headaches t first line agents reserve for post-mi/chf Cause fatigue and decreased heart rate Adversely affect glucose; mask hypoglycemic awareness Cause edema; dihydropyridines may be safely combined w/ B-blocker n-dihydropyridines reduce heart rate and proteinuria Hydralazine and minoxidil may cause reflex tachycardia and fluid retention usually require diuretic + B-blocker Centrally-acting Agents terazosin 1-5mg, doxazosin 1-4mg given at bedtime clonidine mg twice daily, methyldopa mg twice daily guanfacine 1-3mg Alpha-blockers may cause orthostatic hypotension Clonidine available in weekly patch formulation for resistant hypertension
6 Considerations for individualizing antihypertensive therapy Indication Antihypertensive drugs Compelling indications (major improvement in outcome independent of blood pressure) Systolic heart failure Post myocardial infarction Proteinuric chronic kidney disease Angina pectoris Atrial fibrillation rate control Atrial flutter rate control ACE inhibitor or ARB, beta blocker, diuretic, aldosterone antagonist* ACE inhibitor, beta blocker, ARB, aldosterone antagonist ACE inhibitor and/or ARB Beta blocker, calcium channel blocker Beta blocker, nondihydropyridine calcium channel blocker Beta blocker, nondihydropyridine calcium channel blocker Likely to have a favorable effect on symptoms in comorbid conditions Benign prostatic hyperplasia Essential tremor Hyperthyroidism Migraine Osteoporosis Raynaud's syndrome Alpha blocker Beta blocker (noncardioselective) Beta blocker Beta blocker, calcium channel blocker Thiazide diuretic Dihydropyridine calcium channel blocker Contraindications Angioedema Bronchospastic disease Depression Liver disease Pregnancy (or at risk for) Second or third degree heart block ACE inhibitor Beta blocker Reserpine Methyldopa ACE inhibitor, ARB, renin inhibitor Beta blocker, nondihydropyridine calcium channel blocker May have adverse effect on comorbid conditions Depression Gout Hyperkalemia Hyponatremia Renovascular disease Beta blocker, central alpha 2 agonist Diuretic Aldosterone antagonist, ACE inhibitor, ARB, renin inhibitor Thiazide diuretic ACE inhibitor, ARB, or renin inhibitor * A benefit from an aldosterone antagonist has been demonstrated in patients with NYHA class III IV heart failure, or decreased left ventricular ejection fraction after a myocardial infarction Adapted from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289:2560.
7 !
What in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationHypertension: Update
Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationImproving Outcomes for Hypertension
Spectrum of Health September 2017 Improving Outcomes for Hypertension Highlights: Recommendations of the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment
More information8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More informationsympatholytics sympatholytics sympatholytics
sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors
More information2017 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults
DETAILED SUMMARY FROM THE 2017 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults A REPORT OF THE American College of Cardiology/ American Heart Association
More informationNew Hypertension Guidelines: How Lower Blood Pressure Targets Affect Medication Safety
New Hypertension Guidelines: How Lower Blood Pressure Targets Affect Medication Safety Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Andrew Straw, PharmD, BC-ADM
More informationGuide to the New Hypertension Guidelines
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Advanced Practice Pharmacist Crow/Northern Cheyenne Hospital Hypertension St Disclosures None Objectives Describe the new hypertension
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationGuide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Disclosures None Objectives Describe the new hypertension staging and blood pressure goals and
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationASEBP and ARTA TARP Drugs and Reference Price by Categories
ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationHypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS
Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationPhysician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationNew classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100
Hypertension 1 Definition Hypertension can be defined as a condition where blood pressure is elevated to an extent that clinical benefit is obtained from blood pressure lowering. it is an important risk
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationDROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC
DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC Pharmacotherapy of HTN Rationale for reducing arterial pressure Reduce cardiac output Reduce heart rate Reduce stroke
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationLayered Approaches to Studying Drug Responses
Layered Approaches to Studying Drug Responses Brian B Hoffman, MD Chief of Medicine VA Boston Health Care System Professor of Medicine Harvard Medical School Conflict of Interest: US Federal Grant Funding
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationPharmacologic Management of Hypertension
Current Concepts In Management of Fernando Vega, MD Secondary - Definition Renovascular Disease (The kidney doesn t get impressed by blood pressure) Renovascular stenosis Renal artery stenosis Fibromuscular
More informationDifficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment
Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment Dmitri Vasin M.D. Nephrologist and ASH certified clinical hypertension specialist Bremerton, WA, USA Johnson
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationAntihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationHypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly
Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2015 Hypertension Management: Making Sense of Guidelines and Therapy
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPrevention of Cardiovascular Events in Hypertension and CAD & Management of Hypertension in HF of Ischemic origin
"Insight Heart" is also available at www.squarepharma.com.bd Vol: 911 No: 4; 4; 2012 2015 Prevention of Cardiovascular Events in Hypertension and CAD Drug-eluting & Management of Hypertension in HF of
More informationFactors Involved in Poor Control of Risk Factors
Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationHypertension Management. complications including stroke, dementia, coronary artery disease, left ventricular dysfunction, kidney
Hypertension Management Hypertension affects 19.7% of adult Canadians and is one of the most important modifiable risk factors for cardiovascular disease. 1 The prevalence continues to increase with more
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationTREATMENT OF HYPERTENSION
TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and
More informationANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut
ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure
More information8/19/2016. No Conflicts. I struggled with everything cardiac in nursing school.
Cindy Weston, DNP, RN, CCRN, CNS CC, FNP BC Assistant Professor, Texas A&M Health Science Center College of Nursing Describe and define epidemiology and pathophysiology of hypertension Differentiate JNC8
More informationAntihypertensive Agents
Antihypertensive Agents Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.11.2009 1 Süzer Farmakoloji 3. Baskı 2005 2 1 Süzer Farmakoloji 3. Baskı 2005 3 Süzer Farmakoloji 3. Baskı 2005
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationCategories of HTN. Overview of Hypertension. Types of Hypertension
Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is
More informationChapter 2 ~ Cardiovascular system
Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationAntihypertensive Drugs. Nafrialdi
Antihypertensive Drugs Nafrialdi 1 Mechanisms of Blood Pressure Regulation Blood Presure Cardiac Output Peripheral Resistance Heart Rate Stroke volume Vascular tone Vessel elasticity Myocardial contractility
More information